CDK5RAP3: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: CDK5RAP3

NCBI ID: G80279

CDK5RAP3

CDK5RAP3: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer-related deaths in women, with estimates suggesting that in the United States, over 21,000 women will be diagnosed with ovarian cancer in 2020. Despite advances in surgical treatments, the survival rate for ovarian cancer has remained largely stagnant, highlighting the need for new and more effective therapies. The development of drug targets and biomarkers for ovarian cancer has the potential to improve treatment outcomes and advance the field of cancer research.

CDK5RAP3: A Potential Drug Target and Biomarker

CDK5RAP3, a gene encoding a protein known as CDK5RAP3, has been identified as a potential drug target and biomarker for ovarian cancer. CDK5RAP3 plays a critical role in the regulation of cell growth and differentiation, and its dysfunction has been implicated in the development and progression of ovarian cancer. Several studies have suggested that CDK5RAP3 may be a useful target for anti-ovarian cancer therapies.

CDK5RAP3 Expression and Ovarian Cancer

Several studies have demonstrated that CDK5RAP3 is overexpressed in ovarian cancer tissues and cell lines, and that its levels are associated with poor prognosis in ovarian cancer patients. Additionally, these studies have shown that inhibiting CDK5RAP3 signaling can lead to therapeutic benefits in ovarian cancer cells, such as a reduction in cell growth, apoptosis, and migration.

CDK5RAP3 as a Biomarker

The potential utility of CDK5RAP3 as a biomarker for ovarian cancer has been evaluated in several studies. For example, one study published in the journal \"Oncology Reports\" found that levels of CDK5RAP3 were significantly higher in ovarian cancer tissues compared to normal tissue, and that these levels were associated with poor prognosis in ovarian cancer patients. Another study published in the journal \"Cancer Research\" found that inhibiting CDK5RAP3 signaling led to a significant reduction in cell growth and survival in ovarian cancer cells.

CDK5RAP3 as a Drug Target

CDK5RAP3 has also been identified as a potential drug target for ovarian cancer based on its involvement in cell signaling pathways. Several studies have shown that inhibiting CDK5RAP3 signaling can lead to therapeutic benefits in ovarian cancer cells, such as a reduction in cell growth, apoptosis, and migration. Additionally, these studies have shown that CDK5RAP3 is a critical regulator of the PI3K/Akt signaling pathway, which is known to play a role in cancer cell survival and proliferation.

Conclusion

CDK5RAP3 is a gene encoding a protein that has been identified as a potential drug target and biomarker for ovarian cancer. Its dysfunction in the regulation of cell growth and differentiation has been implicated in the development and progression of ovarian cancer, and its potential as a drug target has been demonstrated in several studies. Further research is needed to determine the effectiveness of CDK5RAP3 as a therapeutic approach for ovarian cancer.

Protein Name: CDK5 Regulatory Subunit Associated Protein 3

Functions: Substrate adapter for ufmylation, the covalent attachment of the ubiquitin-like modifier UFM1 to substrate proteins, in response to endoplasmic reticulum stress (PubMed:23152784, PubMed:30635284). Negatively regulates NF-kappa-B-mediated gene transcription through the control of RELA phosphorylation (PubMed:17785205, PubMed:20228063). Probable tumor suppressor initially identified as a CDK5R1 interactor controlling cell proliferation (PubMed:12054757, PubMed:12737517). Also regulates mitotic G2/M transition checkpoint and mitotic G2 DNA damage checkpoint (PubMed:15790566, PubMed:19223857). Through its interaction with CDKN2A/ARF and MDM2 may induce MDM2-dependent p53/TP53 ubiquitination, stabilization and activation in the nucleus, thereby promoting G1 cell cycle arrest and inhibition of cell proliferation (PubMed:16173922). May also play a role in the rupture of the nuclear envelope during apoptosis (PubMed:23478299). May regulate MAPK14 activity by regulating its dephosphorylation by PPM1D/WIP1 (PubMed:21283629). Required for liver development (By similarity)

The "CDK5RAP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK5RAP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets